GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » Research & Development

Autolus Therapeutics (Autolus Therapeutics) Research & Development : $129.81 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Autolus Therapeutics's Research & Development for the three months ended in Mar. 2024 was $30.67 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $129.81 Mil.


Autolus Therapeutics Research & Development Historical Data

The historical data trend for Autolus Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Research & Development Chart

Autolus Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 105.42 134.89 110.84 117.35 130.48

Autolus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.39 36.74 37.24 25.16 30.67

Autolus Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $129.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Autolus Therapeutics  (NAS:AUTL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Autolus Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Autolus Therapeutics (Autolus Therapeutics) Business Description

Traded in Other Exchanges
Address
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics (Autolus Therapeutics) Headlines